Eberconazole
Appearance
Clinical data | |
---|---|
Trade names | Ebernet |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C18H14Cl2N2 |
Molar mass | 329.22 g·mol−1 |
3D model (JSmol) | |
| |
|
Eberconazole is an antifungal drug. As a 1% topical cream, it is an effective treatment for dermatophytosis, candidiasis, and pityriasis.[1][2][3]
It was approved for use in Spain in 2015 and is sold under the trade name Ebernet.[4] It is also approved for use in Panama, Guatemala, Costa Rica, Honduras, and the Dominican Republic.[1]
References
[edit]- ^ a b "Ebernet". NewBridge Pharmaceuticals. Archived from the original on 2016-04-24. Retrieved 2017-01-15.
- ^ del Palacio A, Ortiz FJ, Pérez A, Pazos C, Garau M, Font E (2001). "A double-blind randomized comparative trial: eberconazole 1% cream versus clotrimazole 1% cream twice daily in Candida and dermatophyte skin infections". Mycoses. 44 (5): 173–80. doi:10.1046/j.1439-0507.2001.00632.x. PMID 11486455.
- ^ Repiso Montero T, López S, Rodríguez C, del Rio R, Badell A, Gratacós MR (May 2006). "Eberconazole 1% cream is an effective and safe alternative for dermatophytosis treatment: multicenter, randomized, double-blind, comparative trial with miconazole 2% cream". International Journal of Dermatology. 45 (5): 600–4. doi:10.1111/j.1365-4632.2006.02841.x. PMID 16700802.
- ^ "Eberconazole". Drugs.com. Archived from the original on 2021-01-17. Retrieved 2017-01-15.